GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Avecho Biotechnology Ltd (ASX:AVE) » Definitions » Gross-Profit-to-Asset %

Avecho Biotechnology (ASX:AVE) Gross-Profit-to-Asset % : 17.20% (As of Dec. 2024)


View and export this data going back to 1993. Start your Free Trial

What is Avecho Biotechnology Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Avecho Biotechnology's annualized Gross Profit for the quarter that ended in Dec. 2024 was A$0.93 Mil. Avecho Biotechnology's average Total Assets over the quarter that ended in Dec. 2024 was A$5.43 Mil. Therefore, Avecho Biotechnology's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2024 was 17.20%.


Avecho Biotechnology Gross-Profit-to-Asset % Historical Data

The historical data trend for Avecho Biotechnology's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avecho Biotechnology Gross-Profit-to-Asset % Chart

Avecho Biotechnology Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Gross-Profit-to-Asset %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.46 11.71 20.39 -0.83 13.51

Avecho Biotechnology Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Gross-Profit-to-Asset % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.13 17.64 -12.86 11.09 17.20

Competitive Comparison of Avecho Biotechnology's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Avecho Biotechnology's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Avecho Biotechnology's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Avecho Biotechnology's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Avecho Biotechnology's Gross-Profit-to-Asset % falls into.


;
;

Avecho Biotechnology Gross-Profit-to-Asset % Calculation

Avecho Biotechnology's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2024 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Dec. 2024 )/( (Total Assets (A: Dec. 2023 )+Total Assets (A: Dec. 2024 ))/ count )
=0.833/( (7.335+4.997)/ 2 )
=0.833/6.166
=13.51 %

Avecho Biotechnology's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2024 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Dec. 2024 )/( (Total Assets (Q: Jun. 2024 )+Total Assets (Q: Dec. 2024 ))/ count )
=0.934/( (5.865+4.997)/ 2 )
=0.934/5.431
=17.20 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is two times the semi-annual (Dec. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.


Avecho Biotechnology Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Avecho Biotechnology's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.


Avecho Biotechnology Business Description

Traded in Other Exchanges
Address
Unit A8, 2A Westall Road, Clayton, Melbourne, VIC, AUS, 3168
Avecho Biotechnology Ltd is a research-based biotechnology company engaged in the development, production, sales, and licensing of products incorporating its patented platform technology Tocopheryl Phosphate Mixture (TPM), for the pharmaceutical, skincare, and animal health and nutrition industries. Its segments include Production, Human Health, and other segments. The Production segment, which is the key revenue driver, manufactures and sells TPM and Vital ET for use in drug delivery and cosmetic formulations. The Human Health segment's portfolio covers the delivery of drugs through gels, injectables, and patches including the conduct of research and development activities. It focuses on the development of patches, including TPM/Oxymorphone and TPM/Oxycodone.

Avecho Biotechnology Headlines

No Headlines